Diagnostics, CDK4/6i & ADC

TROPiCS-02

SABCS 2022

Part 3: Testing for TROP-2 not needed / no prognostic…

E. Senkus, D. Lüftner, N. Harbeck, B. Pistilli, S. Paluch-Shimon

RXponder; TAILORX

SABCS 2022

Part 1: Encouraging data that supports treatment…

E. Senkus, D. Lüftner, N. Harbeck, B. Pistilli, S. Paluch-Shimon

SWOG S1207; monarchE; RIGHT choice

SABCS 2022

Part 2: Treamtent options in high-risk breast cancer

E. Senkus, D. Lüftner, N. Harbeck, B. Pistilli, S. Paluch-Shimon

DESTINY-Breast02 & Breast03

DESTINY-Breast 02; DESTINY-Breast 03

SABCS 2022

Practice Changing ADC data confirmed

D. Lüftner, A. Gennari, M. Untch, G. Guliano

New Treatment Perspectives

STIC CTC

SABCS 2022

New insights: Are CTCs predictive or not?

W. Janni, N. Harbeck, V. Dieras, S. Tolaney, E. Ciruelos

CAPitello-291; PACE

SABCS 2022

New treatment perspectives in luminal breast cancer

W. Janni, S. Tolaney, E. Ciruelos, V. Dieras, N. Harbeck

EMERALD; SERENA-2

SABCS 2022

SERDs - who benefits? ESR1 testing required?

N. Harbeck, E. Ciruelos, S. Tolaney, W. Janni, V. Dieras

CDK4/6i, ADC, Pregnancy

RIGHT Choice

SABCS 2022

RIGHT choice against Chemotherapy for aggressive…

A. Schneeweiss, A. Gennari, H. Rugo, P. Fasching

monarchE

SABCS 2022

monarchE confirms increasing benefit. What are the real…

H. Rugo, A. Gennari, A. Schneeweiss, P. Fasching

POSITIVE

SABCS 2022

New evidence regarding the chance of pregnancies in EBC

A. Schneeweiss, A. Gennari, H. Rugo, P. Fasching

TROPiCS-02

SABCS 2022

ADC: Do we need a target? Do we need a predicitve…

A. Schneeweiss, A. Gennari, H. Rugo, P. Fasching

EBC Highlights

monarchE

SABCS 2022

Abemaciclib as standard of in high-risk HR+ HER2-…

Andreas Schneeweiss, MD

APT

SABCS 2022

Adjuvant TH confirms excellent logn-term follow-up

Sara Tolaney, MD

TailorX

SABCS 2022

Chemo without benefit in node-negative disease

Nadia Harbeck, MD

monarchE

SABCS 2022

Time to reconsider Ki-67 threshold?!

Nadia Harbeck, MD

POSITIVE

SABCS 2022

First trial about pregnancy in premenopausal early BC…

Eva Ciruelos, MD

SABCS 2022

Platin-based neoadjuvant therapy in early TNBC: impact…

Eva Ciruelos, MD

IDEAL

SABCS 2022

Benefit of extended adjuvant treatment with endocrine…

Eva Ciruelos, MD

POSITIVE

SABCS 2022

Interruption of endocrine therapy in case of desire to…

Diana Lüftner, MD

TRIO-US B-12 TALENT

SABCS 2022

T-DXd as (neo)adjuvant treatment HR+/HER2- patients

Giuseppe Curigliano, MD

monarchE

SABCS 2022

monarchE confirms data once more.

Wolfgang Janni, MD

POSITIVE

SABCS 2022

POSITIVE-Trial shwos that temporal therapy interruption…

Carmen Criscitiello, MD

POSITIVE

SABCS 2022

Good news for young patients

Karen Gelmon, MD

EBC highlights - Multilanguage

POSITIVE

SABCS 2022

El primer estudio sobre la gestación en pacientes con…

Eva Ciruelos, MD

SABCS 2022

Neoadyuvancia con carboplatino en cáncer de mama precoz…

Eva Ciruelos, MD

SABCS 2022

T-DXd as (neo)adjuvant treatment HR+/HER2- patients

Giuseppe Curigliano, MD

IDEAL

SABCS 2022

Beneficio del tratamiento hormonal extendido según…

Eva Ciruelos, MD

POSITIVE

SABCS 2022

POSITIVE-Trial dimostra che l'interruzione temporanea…

Carmen Criscitiello, MD

MBC highlights

EMERALD; SERENA-2

SABCS 2022

Highlights on oral SERDS in HR+ mBC

Shani Paluch-Shimon, MD

SERENA-2

SABCS 2022

SERENA-2 showed better PFS by camizestrant compared…

Carmen Criscitiello, MD

RIGHT Choice

SABCS 2022

A shift from chemotherapy to CDK4/6

Shani Paluch-Shimon, MD

RIGHT choice

SABCS 2022

Targeted approach for endocrine responsive visceral…

Alessandra Gennari, MD

ROSET-BM

SABCS 2022

Progress in research and clinic

Volkmar Müller, MD

MBC Highlights - Multilanguage

RIGHT choice

SABCS 2022

Il miglior approccio per la malattia…

Alessandra Gennari, MD

EMERALD; SERENA-2

SABCS 2022

Highlights on oral SERDS in HR+ mBC

Shani Paluch-Shimon, MD

SERENA-2

SABCS 2022

SERENA-2 ha mostrato una migliore PFS grazie a…

Carmen Criscitiello, MD

MBC highlights CDK4/6i

RIGHT Choice

SABCS 2022

RIB + ET appears to be the better option than…

Andreas Schneeweiss, MD

PACE

SABCS 2022

Continuing Palbociclib beyond progression does not…

Sara Tolaney, MD

RIGHT Choice

SABCS 2022

CDK4/6 inhibitors - a preferred option also for the…

Elżbieta Senkus, MD

RIGHT Choice

SABCS 2022

HR+/HER2-: Who still needs chemotherapy?

Volkmar Müller, MD

DETECT V

SABCS 2022

De-escalation in triple positive MammaCa

Volkmar Müller, MD

RIGHT Choice

SABCS 2022

Endocrine combination despite visceral crisis

Diana Lüftner, MD

RightChoice

SABCS 2022

Ribociclib + endocrine in high risk HR+/HER2- MBC…

Wolfgang Janni, MD

RIGHT Choice

SABCS 2022

Treatment alternatives to chemotherapy for visceral…

Peter Fasching, MD

MBC highlights CDK4/6i - Multilanguage

RIGHT Choice

SABCS 2022

Inhibitory CDK4/6 opcją z wyboru również u chorych…

Elżbieta Senkus, MD

MBC highlights ADC

DESTINY-Breast02; DESTINY-Breast03

SABCS 2022

Robust benefit of T-Dxd confirmed with new data

Sara Tolaney, MD

DESTINY-Breast03

SABCS 2022

Clinically relevant and statistically significant…

Javier Cortés, MD

DESTINY-Breast02

SABCS 2022

Great data - as usual with T-Dxd

Nadia Harbeck, MD

DESTINY-Breast03

SABCS 2022

T-Dxd - ready for prime time in the 2nd line

Nadia Harbeck, MD

DESTINY-Breast02; DESTINY-Breast03

SABCS 2022

T-Dxd keeps us excited

Karen Gelmon, MD

DESTINY-Breast02, DESTINY-Breast03

SABCS 2022

Optimal side effect management required

Volkmar Müller, MD

DESTINY-Breast02

SABCS 2022

T-DXd as therapy of choice even after T-DM1 in HER2+…

Andreas Schneeweiss, MD

DESTINY-Breast02

SABCS 2022

TDXd is the prefered option for pts previously treated…

Javier Cortés, MD

DESTINY-Breast03

SABCS 2022

T-DXd new standard after pretreatment with trastuzumab…

Andreas Schneeweiss, MD

TRIO-US B-12 TALENT

SABCS 2022

Chemotherapy-free (neo)adjuvant treatment seems…

Andreas Schneeweiss, MD

DESTINY-Breast03

SABCS 2022

Important OS update for T-DXd

Veronique Dieras, MD

EMERALD; SERENA-2; CAPItello-921; DESTINY-Breast 02; DESTINY-Breast 03

SABCS 2022

Positive data for ER+ and HER2+ breast cancer

Giuseppe Curigliano, MD

DESTINY-Breast02; DESTINY-Breast03

SABCS 2022

T-DXd with so far unkown efficacy

Elżbieta Senkus, MD

MBC highlights ADC - Multilanguage

DESTINY-Breast02; DESTINY-Breast03

SABCS 2022

T-DXd – skuteczność, jakiej dotąd nie znaliśmy

Elżbieta Senkus, MD

DESTINY-Breast02

SABCS 2022

TDXd es la primera opción para pacientes tratados…

Javier Cortés, MD

SABCS 2022

Positive data for ER+ and HER2+ breast cancer

Giuseppe Curigliano, MD

DESTINY-Breast03

SABCS 2022

Importante actualisation des données de survie globale…

Véronique Dieras, MD

DESTINY-Breast03

SABCS 2022

Beneficio clínicamente y estadísticamente significativo…

Javier Cortés, MD

MBC highlights SERD

EMERALD; SERENA-2

SABCS 2022

A new drug in the endocrine landscape

Barbara Pistilli, MD

EMERALD; SERENA-2

SABCS 2022

oral SERDs on the rise?

Wolfgang Janni, MD

EMERALD; SERENA-2; CAPItello-921; DESTINY-Breast 02; DESTINY-Breast 03

SABCS 2022

Positive data for ER+ and HER2+ breast cancer

Giuseppe Curigliano, MD

EMERALD; SERENA-2; PACE

SABCS 2022

Oral SERDs are superior

Karen Gelmon, MD

MBC highlights SERD - Multilanguage

EMERALD; SERENA-2

SABCS 2022

Une nouvelle molécule dans le traitement hormonal du…

Barbara Pistilli, MD

SABCS 2022

Positive data for ER+ and HER2+ breast cancer

Giuseppe Curigliano, MD

EMERALD; SERENA-2

SABCS 2022

Una nouva molecola nel trattamento ormonale del tumore…

Barbara Pistilli, MD

MBC highlights Varia

DETECT V

SABCS 2022

Triple-positive MBC does not require chemotherapy.

Wolfgang Janni, MD

GeparOLA

SABCS 2022

Olaparib as an alternative to carboplatin in aggressive…

Peter Fasching, MD

EMERALD; SERENA-2; DESTINY-Breast 02; DESTINY-Breast 03

SABCS 2022

ADC or other therapies after CDK4/6

Michael Untch, MD

STIC CTC

SABCS 2022

CTC count may help in therapy decisions

Veronique Dieras, MD

CAPitello-291

SABCS 2022

Promising new player in the second line setting in…

Elżbieta Senkus, MD

SABCS 2022

Estradiol withdrawal affects the micromillieu in the…

Diana Lüftner, MD

CAPitello-291

SABCS 2022

Capivasertib - A drug for allcomers

Alessandra Gennari, MD

POSITIVE

SABCS 2022

Pregnancies after primary breast cancer

Wolfgang Janni, MD

SABCS 2022

Her2-low discordance rate at 40%

Diana Lüftner, MD

STIC CTC

SABCS 2022

CTCs with metastatic breast cancer re-visited

Wolfgang Janni, MD

CAPitello-291

SABCS 2022

AKT inhibitor capivasertib in HR+ mBC

Peter Fasching, MD

EMERALD; SERENA-2; CAPItello-921; DESTINY-Breast 02; DESTINY-Breast 03

SABCS 2022

Positive data for ER+ and HER2+ breast cancer

Giuseppe Curigliano, MD

MBC highlights Varia - Multilanguage

SABCS 2022

Positive data for ER+ and HER2+ breast cancer

Giuseppe Curigliano, MD

CAPitello-291

SABCS 2022

Obiecująca nowa opcja w drugiej linii zaawansowanego,…

Elżbieta Senkus, MD

CAPitello-291

SABCS 2022

Capivasertib un nuovo standard per tutti?

Alessandra Gennari, MD

STIC CTC

SABCS 2022

Le compte des CTC peut orienter la décision…

Véronique Dieras, MD

eBC Year in Review

APHINITY; KAITLIN; perELISA; ADAPT; IMpassion050

Year in Review 2022

HER2+ - no new approval but long-term follow up data…

N. Harbeck, A. Gennari, H. Rugo, E. Senkus

TailorX; ADAPT; monarchE; iSPY; POSITIVE; OlympiA

Year in Review 2022

HR+ - Practice changing data - which therapy for which…

N. Harbeck, A. Gennari, H. Rugo, E. Senkus

KEYNOTE-522; NACT Gupta et al.; OlympiA

Year in Review 2022

TNBC - Practice changing data lead to new approvals -…

N. Harbeck, A. Gennari, H. Rugo, E. Senkus

mBC Year in Review

RIGHT Choice; MONARCH 3; PALOMA-2; EMERALD; AMEERA; acelERA BC

SABCS 2022

The Right Choices? CDK4/6i vs. Chemo, SERDs & ESR1?

R. Dent, V. Diéras, C. Criscitiello, M. Untch

DESTINY-Breast02; DESTINY-Breast03; TROPICS-02; DESTINY-Breast04

SABCS 2022

New Indications: ADCs & HER2-low

V. Diéras, R. Dent, C. Criscitiello, M. Untch

DESTINY-Breast02; DESTINY-Breast03; DETECT V; HER2CLIMB; TUXEDO-1; KEYNOTE-355

SABCS 2022

Dealing with Brain mets / Update TNBC

V. Diéras, R. Dent, C. Criscitiello, M. Untch